Literature DB >> 21766092

An evaluation of the use of serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea.

W Gordon Brydon1, Pearl Culbert, Kathleen Kingstone, Ann Jarvie, Marietta Iacucci, Merel Tenhage, Subrata Ghosh.   

Abstract

BACKGROUND: Bile acid malabsorption (BAM) is a recognized cause of watery diarrhea, often diagnosed empirically based on clinical response to cholestyramine. The radionuclide selenium-labelled homocholic acid-taurine whole body retention test is expensive, labour intensive and of limited availability.
OBJECTIVE: To report on the clinical performance of serum 7-alphahydroxy-4-cholesten-3-one (7HCO) as a test of BAM in adult patients with unexplained diarrhea.
METHODS: Patients with unexplained diarrhea were investigated over a three-year period. Final diagnosis was determined based on medical history and investigations, serum levels of 7HCO and response to cholestyramine. ROC analysis was used to determine the ideal upper reference range cut-off value to optimize sensitivity/specificity for BAM. Time of blood specimen collection was recorded to investigate possible variation in results throughout the working day.
RESULTS: ROC analysis yielded a sensitivity/specificity of 90%/77% for type 1 BAM (ileal disease/resection) and 97%/74% for type 2 BAM (idiopathic) using 30 ng/mL as the upper limit of normal for serum 7HCO when compared with all other patients. Of 813 patients, 196 tested positive. Serum 7HCO levels were significantly higher in blood specimens that were collected between 12:00 and 13:00 (median 24 ng/mL) than in specimens collected between 09:00 and 10:00 (median 17 ng/mL) (P<0.05).
CONCLUSION: Serum 7HCO testing is a simple, sensitive, noninvasive, inexpensive alternative to other more commonly used tests for BAM. Time of specimen collection, however, resulted in small but significant result variations and, although unlikely to have much impact on test value, it should ideally be standardized.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766092      PMCID: PMC3142604          DOI: 10.1155/2011/701287

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  11 in total

1.  UK nuclear medicine survey 2003-2004.

Authors:  David Hart; Barry F Wall
Journal:  Nucl Med Commun       Date:  2005-11       Impact factor: 1.690

2.  Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea.

Authors:  W G Brydon; H Nyhlin; M A Eastwood; M V Merrick
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-02       Impact factor: 2.566

3.  Reversed-phase high-performance liquid chromatographic determination of 7 alpha-hydroxy-4-cholesten-3-one in human serum.

Authors:  L Pettersson; C G Eriksson
Journal:  J Chromatogr B Biomed Appl       Date:  1994-07-01

4.  The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man.

Authors:  M Axelson; I Björkhem; E Reihnér; K Einarsson
Journal:  FEBS Lett       Date:  1991-06-24       Impact factor: 4.124

5.  Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis.

Authors:  Cecilia Gälman; Bo Angelin; Mats Rudling
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

6.  Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption.

Authors:  Antal Bajor; Anders Kilander; Anita Fae; Cecilia Gälman; Olof Jonsson; Lena Ohman; Mats Rudling; Henrik Sjövall; Per-Ove Stotzer; Kjell-Arne Ung
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-04       Impact factor: 2.566

7.  Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man.

Authors:  M Axelson; A Aly; J Sjövall
Journal:  FEBS Lett       Date:  1988-11-07       Impact factor: 4.124

Review 8.  Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

Authors:  L Wedlake; R A'Hern; D Russell; K Thomas; J R F Walters; H J N Andreyev
Journal:  Aliment Pharmacol Ther       Date:  2009-06-30       Impact factor: 8.171

9.  Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry.

Authors:  M Camilleri; A Nadeau; W J Tremaine; J Lamsam; D Burton; S Odunsi; S Sweetser; R Singh
Journal:  Neurogastroenterol Motil       Date:  2009-03-13       Impact factor: 3.598

10.  Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test.

Authors:  S Eusufzai; M Axelson; B Angelin; K Einarsson
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

View more
  9 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

2.  Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.

Authors:  Robert Battat; Marjolijn Duijvestein; Niels Vande Casteele; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Larry Mimms; Judson McFarland; Kelly D Hester; Mark Renshaw; Anjali Jain; William J Sandborn; Brigid S Boland
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-15       Impact factor: 11.382

Review 3.  Pathophysiology and Clinical Management of Bile Acid Diarrhea.

Authors:  Giovanni Marasco; Cesare Cremon; Maria Raffaella Barbaro; Francesca Falangone; Davide Montanari; Federica Capuani; Giada Mastel; Vincenzo Stanghellini; Giovanni Barbara
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

Review 4.  Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment.

Authors:  Alan N Barkun; Jonathan Love; Michael Gould; Henryk Pluta; Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

5.  Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea.

Authors:  Sanjeev S Pattni; W Gordon Brydon; Tracy Dew; Julian R F Walters
Journal:  Clin Transl Gastroenterol       Date:  2012-07-26       Impact factor: 4.488

6.  Faecal Calprotectin and 7-α Cholestenone Levels in Microscopic Colitis: Experience from Edinburgh.

Authors:  Matt Davie; Rebecca Trimble; Alexander R Robertson; Anastasios Koulaouzidis
Journal:  Clin Exp Gastroenterol       Date:  2020-05-04

7.  Methods for diagnosing bile acid malabsorption: a systematic review.

Authors:  Ivan Lyutakov; Francesco Ursini; Plamen Penchev; Giacomo Caio; Antonio Carroccio; Umberto Volta; Roberto De Giorgio
Journal:  BMC Gastroenterol       Date:  2019-11-14       Impact factor: 3.067

8.  Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea.

Authors:  Daniel C Sadowski; Michael Camilleri; William D Chey; Grigorios I Leontiadis; John K Marshall; Eldon A Shaffer; Frances Tse; Julian R F Walters
Journal:  J Can Assoc Gastroenterol       Date:  2019-12-06

9.  Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.

Authors:  Richard N Appleby; Iman Moghul; Shahid Khan; Michael Yee; Pinelope Manousou; Tracy Dew Neal; Julian R F Walters
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.